Cannara Biotech (8CB0) Stock Price & Analysis
8CB0 Stock Chart & Stats
- Day’s Range
- EUR 1.26 - EUR 1.29
- 52-Week Range
- EUR 0.83 - EUR 1.35
- Previous Close
- EUR 1.31
- Volume
- N/A
- Average Volume (3M)
- 50
- Market Cap
- EUR 130.56M
- Enterprise Value
- EUR 183.06M
- Total Cash (Recent Filing)
- EUR 21.81M
- Total Debt (Recent Filing)
- EUR 37.00M
- Price to Earnings (P/E)
- 18.4
- Beta
- 0.31
- Next Earnings
- Nov 24, 2026 (Est.)
- EPS Estimate
- 0.02
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Strong Revenue Growth
Sustained double-digit revenue growth indicates expanding demand and improving distribution rather than a one-time gain. Continued top-line scaling can support operating leverage, strengthen brand presence, and provide resources for capacity investment over the next several quarters.
Consistent Profitability And Cash Generation
A long record of positive adjusted EBITDA and operating cash flow demonstrates that the operating model is generating recurring financial support for the business. This consistency improves resilience and reduces reliance on external funding as Cannara expands.
Capacity And Distribution Expansion
Accelerated production expansion combined with broad distribution gives Cannara a larger platform to capture regulated-market demand. The existing-footprint runway toward 100,000 kg could support future volume growth while wider availability reinforces market access and brand velocity.
Bears Say
Margin Compression And Earnings Volatility
Recent margin deterioration shows that revenue growth has not translated consistently into operating profitability. Product mix and cost pressure could limit earnings conversion, making future results more sensitive to pricing, cultivation efficiency, and the pace of operational improvement.
Expansion Is Reducing Free Cash Flow
Large expansion investments are absorbing cash even while the company remains profitable, reducing near-term financial flexibility. If capital spending continues ahead of capacity benefits, lower free cash flow could constrain debt reduction, reinvestment choices, or the ability to absorb weaker trading.
Competitive Pricing And Category Pressure
Intensifying competition can make distribution gains more expensive and weaken realized pricing or volumes in important categories. Higher marketing requirements and targeted price adjustments may therefore limit margin sustainability even as Cannara expands its product reach.
Cannara Biotech News
8CB0 FAQ
What was Cannara Biotech’s price range in the past 12 months?
What is Cannara Biotech’s market cap?
When is Cannara Biotech’s upcoming earnings report date?
How were Cannara Biotech’s earnings last quarter?
Is Cannara Biotech overvalued?
Does Cannara Biotech pay dividends?
What is Cannara Biotech’s EPS estimate?
How many shares outstanding does Cannara Biotech have?
What happened to Cannara Biotech’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Cannara Biotech?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Cannara Biotech
Cannara Biotech Inc., alongside its affiliated entities, specializes in the indoor cultivation, processing, and distribution of cannabis and related products across Canada. The company operates with a dual business model, encompassing both cannabis operations and real estate activities. Its diverse product portfolio is marketed under distinct brand names such as TRIBAL, nugz, and ORCHID CBD. Distribution is managed through both wholesale channels and online retail platforms. Established in 2017, Cannara Biotech Inc. maintains its headquarters in Saint-Laurent, Canada.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Zohar Krivorot
- Employees
- 452
- Website
- cannara.ca
- Address
- 333 Decarie Blvd. Suite 200, Saint-Laurent, QC, H4N 3M9, CA
Cannara Biotech (8CB0) Earnings & Revenues
8CB0 Company Deck
8CB0 Earnings Call
Earnings Call SentimentPositive
The call presents a broadly positive operational and financial picture: double-digit revenue growth (16% QoQ), continued profitability (adjusted EBITDA up 11% and 21 consecutive positive quarters), strengthened market penetration (national share gains and record monthly shares in Ontario and Alberta), accelerated capacity expansion and strategic partnerships (Medican acquisition, Blue River technology, CAD 21M Curaleaf agreement). Notable near-term negatives include lower quarterly free cash flow and operating cash flow versus the prior year driven by higher expansion capex, a modest dip in gross margin from product mix, higher receivables and inventory, and competitive pressures in certain categories. On balance, the highlights — consistent profitability, expanding distribution and market share, accelerated capacity rollout, and strategic deals — outweigh the lowlights tied to timing, investment-driven cash flow effects, and category competition.
View all DE:8CB0 earnings summaries8CB0 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 16 | 2 | 4 |
| Technical Analysis | 4 | 2 | 4 |
| Moving Averages | 12 | 0 | 0 |
